Clinical Trials

340 enrolled 23 charts

Head & Neck

Head and Neck Neoplasms

NCT07271446 2025-12-09

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

8 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02191891 2025-06-25

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

32 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT01853826 2025-04-11

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

481 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04206787 2025-02-28

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

72 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT02597946 2025-02-19

Afatinib in NSCLC With HER2 Mutation

18 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT01649271 2025-02-11

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

13 enrolled 11 charts

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT00950742 2025-02-10

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

18 enrolled 14 charts

Breast

Breast Neoplasms

NCT01214616 2025-02-07

BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

17 enrolled 15 charts

Neoplasms

NCT02171650 2025-01-23

BIBW 2992 in Patients With Advanced Solid Tumors

7 enrolled

Neoplasms

NCT04795245 2024-12-27

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

805 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT04750824 2024-09-19

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

110 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT04179890 2023-05-25

UpSwinG

462 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT02440854 2022-04-27

Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings

80 enrolled 37 charts

Carcinoma, Non-Small-Cell Lung

NCT04552535 2022-01-11

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

200 enrolled 18 charts

Squamous Non-small Cell Lung Cancer

NCT02372006 2021-03-04

Trial of Afatinib in Pediatric Tumours

Phase 1/2 Completed

56 enrolled 23 charts

Sarcoma

Rhabdomyosarcoma, Neuroectodermal Tumors

NCT03370770 2020-12-24

Afatinib Osimertinib Sequencing NIS

204 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT02780687 2020-11-18

LUX-Bladder 1

42 enrolled 16 charts

Genitourinary

Urologic Neoplasms

NCT01466660 2020-04-07

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

319 enrolled 19 charts

Lung Neoplasms

NCT02514174 2020-03-30

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Phase 4 Completed

25 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02047903 2020-01-09

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

161 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT01953913 2019-08-12

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

542 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT01125566 2019-07-18

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

508 enrolled 13 charts

Breast

Breast Neoplasms

NCT00977431 2019-02-18

Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

36 enrolled 16 charts

CNS

Glioblastoma

NCT01523587 2019-02-15

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

795 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT01206816 2019-02-01

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

57 enrolled 19 charts

Neoplasms

NCT02208843 2018-12-17

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase 4 Completed

60 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT01121393 2018-12-14

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

364 enrolled 28 charts 1 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT02131259 2018-09-07

Long-term Observation PMS for Afatinib

1,605 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

345 enrolled 23 charts 1 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT01345682 2018-02-15

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

483 enrolled 21 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00801294 2017-12-29

A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer

46 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02020577 2017-06-22

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

58 enrolled 13 charts

Neoplasms

NCT02044380 2017-03-31

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

14 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung

NCT01814553 2016-10-31

ADAM-Afatinib Diarrhea Assessment and Management

40 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT00525148 2016-09-16

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

129 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT00514943 2016-07-26

BIBW 2992 (Afatinib) in Head & Neck Cancer

124 enrolled 31 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00656136 2016-07-26

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

585 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00809133 2016-03-14

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

83 enrolled 42 charts

Neoplasms

NCT01090011 2015-10-02

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

171 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT01441596 2015-09-07

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

121 enrolled 10 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02171663 2015-01-28

Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors

43 enrolled

Neoplasms

NCT00706628 2015-01-15

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

87 enrolled 20 charts

Genitourinary

Prostatic Neoplasms

NCT00711594 2015-01-15

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

74 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT02171637 2014-06-24

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

38 enrolled

Neoplasms

NCT02171676 2014-06-24

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

40 enrolled

Neoplasms

NCT02171702 2014-06-24

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours

53 enrolled

Neoplasms

NCT02171728 2014-06-24

Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

30 enrolled

Neoplasms

NCT02171741 2014-06-24

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

31 enrolled